Stock Track | Omnicell Stock Soars on Strong Q3 Results and Raised Guidance

Stock Track

Oct 30, 2024

Omnicell Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, saw its stock price surge 19.45% on October 30, 2024, after reporting impressive third-quarter results that surpassed analyst expectations. The company's strong performance and optimistic outlook for the remainder of the year fueled investor confidence, resulting in a significant upward movement in its share price.

The key highlights from Omnicell's third-quarter financial report include:

Adjusted earnings per share of $0.56, beating the consensus estimate of $0.40
Revenue of $282.4 million, exceeding the estimated $280.4 million
Raised full-year 2024 non-GAAP EBITDA guidance to $129 million - $134 million
Increased full-year 2024 non-GAAP earnings per share guidance to $1.65 - $1.72

Omnicell's strong performance was driven by robust demand for its innovative solutions and services, which resonated well with the market despite a challenging macroeconomic environment for some healthcare customers. The company's outcomes-centric approach and customer-first focus have been instrumental in driving growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143203935"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143203935\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143203935?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143203935","market":"us","top_or_hot":-1,"title":"Stock Track | Omnicell Stock Soars on Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>Omnicell Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, saw its stock price surge 19.45% on October 30, 2024, after reporting impressive third-quarter results that surpassed analyst expectations. The company's strong performance and optimistic outlook for the remainder of the year fueled investor confidence, resulting in a significant upward movement in its share price.</p>\n\n<p>The key highlights from Omnicell's third-quarter financial report include:\n<ul>\n<li>Adjusted earnings per share of $0.56, beating the consensus estimate of $0.40</li>\n<li>Revenue of $282.4 million, exceeding the estimated $280.4 million</li>\n<li>Raised full-year 2024 non-GAAP EBITDA guidance to $129 million - $134 million</li>\n<li>Increased full-year 2024 non-GAAP earnings per share guidance to $1.65 - $1.72</li>\n</ul>\n</p>\n\n<p>Omnicell's strong performance was driven by robust demand for its innovative solutions and services, which resonated well with the market despite a challenging macroeconomic environment for some healthcare customers. The company's outcomes-centric approach and customer-first focus have been instrumental in driving growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Omnicell Stock Soars on Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Omnicell Stock Soars on Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Omnicell Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, saw its stock price surge 19.45% on October 30, 2024, after reporting impressive third-quarter results that surpassed analyst expectations. The company's strong performance and optimistic outlook for the remainder of the year fueled investor confidence, resulting in a significant upward movement in its share price.</p>\n\n<p>The key highlights from Omnicell's third-quarter financial report include:\n<ul>\n<li>Adjusted earnings per share of $0.56, beating the consensus estimate of $0.40</li>\n<li>Revenue of $282.4 million, exceeding the estimated $280.4 million</li>\n<li>Raised full-year 2024 non-GAAP EBITDA guidance to $129 million - $134 million</li>\n<li>Increased full-year 2024 non-GAAP earnings per share guidance to $1.65 - $1.72</li>\n</ul>\n</p>\n\n<p>Omnicell's strong performance was driven by robust demand for its innovative solutions and services, which resonated well with the market despite a challenging macroeconomic environment for some healthcare customers. The company's outcomes-centric approach and customer-first focus have been instrumental in driving growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"","article_id":"1143203935","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143203935","pubTimestamp":1730295322,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Omnicell Inc. , a leading provider of medication management solutions, saw its stock price surge 19.45% on October 30, 2024, after reporting impressive third-quarter results that surpassed analyst expectations. The company's strong performance and optimistic outlook for the remainder of the year fueled investor confidence, resulting in a significant upward movement in its share price.The key highlights from Omnicell's third-quarter financial report include:. Adjusted earnings per share of $0.56,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell"},"translate_title":"股票赛道Omnicell股价因强劲的第三季度业绩和上调指引而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1},"content_text":"Omnicell Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, saw its stock price surge 19.45% on October 30, 2024, after reporting impressive third-quarter results that surpassed analyst expectations. The company's strong performance and optimistic outlook for the remainder of the year fueled investor confidence, resulting in a significant upward movement in its share price.\nThe key highlights from Omnicell's third-quarter financial report include:\n\nAdjusted earnings per share of $0.56, beating the consensus estimate of $0.40\nRevenue of $282.4 million, exceeding the estimated $280.4 million\nRaised full-year 2024 non-GAAP EBITDA guidance to $129 million - $134 million\nIncreased full-year 2024 non-GAAP earnings per share guidance to $1.65 - $1.72\n\nOmnicell's strong performance was driven by robust demand for its innovative solutions and services, which resonated well with the market despite a challenging macroeconomic environment for some healthcare customers. The company's outcomes-centric approach and customer-first focus have been instrumental in driving growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}